Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition

被引:32
作者
Callender, GG
Rosen, HR
Roszkowski, JJ
Lyons, GE
Li, ML
Moore, T
Brasic, N
Mckee, MD
Nishimura, MI
机构
[1] Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA
[2] Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Boulder, CO 80309 USA
关键词
D O I
10.1002/hep.21157
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) has been reported to elicit B and T cell immunity in infected patients. Despite the presence of antiviral immunity, many patients develop chronic infections leading to cirrhosis, hepatocellular carcinoma, and liver failure that can require transplantation. We have previously described the presence of HLA-A2-restricted, HCV NS3-reactive cytotoxic T lymphocytes (CTL) in the blood of HLA-A2(-) liver transplantation patients that received an HLA-A2(+) liver allograft. These T cells are analogous to the "allospecific" T cells that have been described in hematopoietic stem cell transplantation patients. It has been speculated that allospecific T cells express high-affinity T cell receptors (TCRs). To determine if our HCV-reactive T cells expressed TCRs with relatively high affinity for antigen, we identified and cloned a TCR from an allospecific HLA-A2-restricted, HCV-NS3:1406-1415-reactive CD8(+) T cell clone and expressed this HCV TCR in Jurkat cells. Tetramer binding to HCV TCR-transduced Jurkat cells required CD8 expression, whereas antigen recognition did not. In conclusion, based on the reactivity of the TCR-transduced Jurkat cells, we have identified a TCR that transfers anti-HCV reactivity to alternate effectors. These data suggest this high affinity HCV-specific TCR might have potential new immunotherapic implications.
引用
收藏
页码:973 / 981
页数:9
相关论文
共 34 条
[1]   Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy [J].
AlexanderMiller, MA ;
Leggatt, GR ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4102-4107
[2]  
ANGLARD P, 1992, CANCER RES, V52, P348
[3]  
Clay TM, 1999, J IMMUNOL, V163, P507
[4]  
COLE DJ, 1995, CANCER RES, V55, P748
[5]   Projecting future complications of chronic hepatitis C in the United States [J].
Davis, GL ;
Albright, JE ;
Cook, SF ;
Rosenberg, DM .
LIVER TRANSPLANTATION, 2003, 9 (04) :331-338
[6]   Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response [J].
Dudley, ME ;
Nishimura, MI ;
Holt, AKC ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 1999, 22 (04) :288-298
[7]   The association between hepatitis C infection and survival after orthotopic liver transplantation [J].
Forman, LM ;
Lewis, JD ;
Berlin, JA ;
Feldman, HI ;
Lucey, MR .
GASTROENTEROLOGY, 2002, 122 (04) :889-896
[8]   Perspectives: towards a peptide-based vaccine against hepatitis C virus [J].
Hunziker, IP ;
Zurbriggen, R ;
Glueck, R ;
Engler, OB ;
Reichen, J ;
Dai, WJ ;
Pichler, WJ ;
Cerny, A .
MOLECULAR IMMUNOLOGY, 2001, 38 (06) :475-484
[9]   SPECIES-RESTRICTED INTERACTIONS BETWEEN CD8 AND THE ALPHA-3 DOMAIN OF CLASS-I INFLUENCE THE MAGNITUDE OF THE XENOGENEIC RESPONSE [J].
IRWIN, MJ ;
HEATH, WR ;
SHERMAN, LA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (04) :1091-1101
[10]   Redirecting T lymphocyte specificity using T cell receptor genes [J].
Kaplan, BLF ;
Yu, DC ;
Clay, TM ;
Nishimura, MI .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2003, 22 (3-4) :229-253